This is the last part of the Business section of the report.
>In a meeting with the FDA on May 29, 2007, we received confirmation that the FDA will accept either positive interim or final analysis of survival from our ongoing Phase 3 D9902B IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) study to support licensure of Provenge. These analyses are event driven, rather than time specific. We anticipate that interim results will be available from our IMPACT study during the second half of 2008. We own worldwide commercialization rights for Provenge<
Right you are slimmy: Provenge's best avg. survival is 4.5 months; GVAX's best avg. survival is 35 months.
Gee, which would you rather take?
Factor in that GVAX is off-the-shelf and less expensive than the autologous Provenge, and you have a scenario in which DNDN is trying to gain approval for a treatment that will be obsolete almost as soon as it hits the market (if it ever does).